Cerveau Announces Singapore Test of Neuro PET Imaging Agent

Cerveau Technologies, a partnership between Beijing Sinotau Pharma and Enigma Biomedical of Toronto, will start a Singapore trial of its PET imaging agent for neurofibrillary tangles (NFTs) in the brain, the first Asia test of the agent. Cerveau develops diagnostics and technology for neurodegenerative disorders including Alzheimer's disease. It in-licensed global rights to the agent, MK-6240, from Merck in early 2017 and has formed numerous collaborations around the globe to test its efficacy. Sinotau holds China rights to the imaging agent. More details.... Stock Symbol: (NYSE: MRK) Share this with colleagues: // //